AJP - Renal Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol (September 13, 2005). doi:10.1152/ajprenal.00289.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/3/F600    most recent
00289.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agarwal, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agarwal, R.
Submitted on July 14, 2005
Accepted on August 30, 2005

Anti-inflammatory Effects of Short-term Pioglitazone Therapy in Men with Advanced Diabetic Nephropathy

Rajiv Agarwal1*

1 Division of Nephrology, Department of Medicine, Indiana University School of Medicine, and Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA

* To whom correspondence should be addressed. E-mail: ragarwal{at}iupui.edu.

Background: Patients with diabetic nephropathy have a high rate of cardiovascular events and mortality. Non-traditional cardiovascular risk factors such as oxidative stress and inflammation are thought to be particularly important in mediating these events. Studies suggest that thiazolidinediones (TZDs) can reduce the level of non-traditional cardiovascular risk in people with or without diabetes mellitus. Whether this benefit occurs in patients with diabetic nephropathy is unknown. I hypothesized that the TZD pioglitazone will mitigate oxidative stress and inflammation compared to glipizide in patients with overt diabetic nephropathy. Methods: Markers of oxidative stress (plasma and urine albumin carbonyl and total protein carbonyls and malondialdheyde), inflammation (WBC count, C-reactive protein, plasma interleukin 6, tumor necrosis factor-{alpha}) and plaque stability (matrix metalloproteinase 9) were measured in frozen samples obtained from patients with overt diabetic nephropathy participating in a randomized, open-label, blinded end-point, 16 week trial with glipizide (n=22) or pioglitazone (n=22). Results: Pioglitazone therapy in men with advanced diabetic nephropathy reduced WBC count by 1,125/µL (p<0.001), CRP by 41% (p=0.042) IL-6 by 38% (p=0.009) and MMP9 by 29% (p=0.016). Specific differential reductions in WBC count of 1,251/µL (p=0.009) and reduction in IL-6 of 58% with pioglitazone (p=0.001) were seen when compared to glipizide. There were no statistically significant changes observed with plasma TNF-{alpha} concentrations or markers of oxidative stress with either hypoglycemic agent. Conclusion: Pioglitazone reduces proinflammatory markers in patients with overt diabetic nephropathy, which indicates potentially beneficial effects on overall cardiovascular risk. This surrogate end-point needs to be confirmed in trials designed to demonstrate cardiovascular protection.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
H. Zhang, J. Saha, J. Byun, M. Schin, M. Lorenz, R. T. Kennedy, M. Kretzler, E. L. Feldman, S. Pennathur, and F. C. Brosius III
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy
Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1071 - F1081.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. J. Ko, Y. S. Kang, S. Y. Han, M. H. Lee, H. K. Song, K. H. Han, H. K. Kim, J. Y. Han, and D. R. Cha
Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2750 - 2760.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Qian, E. Feldman, S. Pennathur, M. Kretzler, and F. C. Brosius III
From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy
Diabetes, June 1, 2008; 57(6): 1439 - 1445.
[Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Dominguez, P. Wu, C. S. Packer, C. Temm, and K. J. Kelly
Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy
Am J Physiol Renal Physiol, September 1, 2007; 293(3): F670 - F679.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
P. C. Fortes, P. H. Versari, A. E.M. Stinghen, and R. Pecoits-Filho
CONTROLLING INFLAMMATION IN PERITONEAL DIALYSIS: THE ROLE OF PD-RELATED FACTORS AS POTENTIAL INTERVENTION TARGETS
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S76 - S81.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Y. Birnbaum, Y. Ye, Y. Lin, S. Y. Freeberg, S. P. Nishi, J. D. Martinez, M.-H. Huang, B. F. Uretsky, and J. R. Perez-Polo
Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat
Circulation, August 29, 2006; 114(9): 929 - 935.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.